Hans de Weers

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022

Retrieved on: 
Tuesday, April 19, 2022
JH, Cancer, Biotechnology, U.S. Securities and Exchange Commission, Janssen, SC, Risk, Risk management, Annual report, MD, Daratumumab, Food, Patient, Lymphoma, Review, Technology, Nasdaq, Johnson & Johnson, Immune system, Food and Drug Administration, Apoptosis, Environment, SEC, Journal, Safety, CD38, Product, USD, Blood, Mab, Hans de Weers, Disease, Antibody, AL, MB, Time, Journal of Immunology, Pharmaceutical industry, Vaccine, Hyaluronidase, Genmab, Halozyme, Multiple myeloma

Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.

Key Points: 
  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
    COPENHAGEN, Denmark; April 19, 2022 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 1,856 million in the first quarter of 2022.
  • Net trade sales were USD 953 million in the U.S. and USD 903 million in the rest of the world.
  • Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize daratumumab.
  • Genmab has the right to seek review of the award, which it must do within a limited period of time.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021

Retrieved on: 
Tuesday, January 25, 2022
Journal of Immunology, Food, Janssen, Food and Drug Administration, Blood, Mab, Product, SEC, JH, U.S. Securities and Exchange Commission, Technology, Daratumumab, CD38, Biotechnology, Lymphoma, Apoptosis, Disease, SC, Environment, Annual report, Journal, USD, Antibody, Cancer, Johnson & Johnson, Patient, Immune system, Risk management, Risk, MD, MB, Hans de Weers, AL, Safety, Pharmaceutical industry, Vaccine, Halozyme, Genmab, Hyaluronidase, Multiple myeloma

Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.

Key Points: 
  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
    Copenhagen, Denmark; January 25, 2022 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 6,023 million in 2021.
  • Net trade sales were USD 3,169 million in the U.S. and USD 2,854 million in the rest of the world.
  • Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize daratumumab.
  • Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.

Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021

Retrieved on: 
Tuesday, October 19, 2021
MB, Biotechnology, Blood, Immune system, Risk, Journal of Immunology, Apoptosis, SC, Journal, Technology, MD, Antibody, Lymphoma, Food and Drug Administration, Daratumumab, JH, Annual report, Disease, Risk management, USD, U.S. Securities and Exchange Commission, Nasdaq, Safety, CD38, Johnson & Johnson, Patient, AL, Janssen, Cancer, SEC, Food, Hans de Weers, Mab, Environment, Product, Pharmaceutical industry, Vaccine

Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.

Key Points: 
  • Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc.
    Copenhagen, Denmark; October 19, 2021 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) formulation (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO in the U.S.), as reported by Johnson & Johnson were USD 1,580 million in the third quarter of 2021.
  • Net trade sales were USD 841 million in the U.S. and USD 739 million in the rest of the world.
  • Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech, Inc. (Janssen) to develop, manufacture and commercialize daratumumab.
  • Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.